 May 17, 2012 |
In April, Kringle Pharma completed Phase Ib clinical trial of recombinant
human HGF in the United States. Primary objectives of the trial, the safety
and pharmacokinetics of multiple intravenous dosing of HGF, were
successfully evaluated. |
